{
    "2021-12-24": [
        [
            {
                "time": "",
                "original_text": "贝达药业今日大宗交易成交3.10万股，成交价93.69元溢价19.85%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "大宗交易",
                        "溢价"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业现1笔大宗交易 共成交290.44万元",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "大宗交易"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "国金证券：给予贝达药业买入评级",
                "features": {
                    "keywords": [
                        "国金证券",
                        "买入评级",
                        "贝达药业"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国金证券给予贝达药业买入评级：贝伐珠单抗新增6项适应症受理",
                "features": {
                    "keywords": [
                        "国金证券",
                        "买入评级",
                        "贝达药业",
                        "贝伐珠单抗",
                        "适应症"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}